E-Newsletter - December 2017

ALLIANCE RESEARCH IN SPOTLIGHT  
2017 SABCS MEETING DECEMBER 5-9

The San Antonio Breast Cancer Symposium (SABCS) provides state-of-the-art information on breast cancer research. SABCS is a five-day program attended by a broad international audience of academic and private researchers and physicians from more than 90 countries. Its goal is to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication and education for a wide spectrum of researchers, health professionals and those with a special interest in breast cancer. The Alliance for Clinical Trials in Oncology was well represented at the 40th Annual Meeting December 5-9.

Here's a snapshot of studies that were presented.
 
CALGB (Alliance) 40502
Long-term Follow-up of CALGB 40502/NCCTG N063H: A Randomized Phase III Trial of Weekly Paclitaxel (P) Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel (NP) or Ixabepilone (Ix) +/- Bevacizumab (B) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer (MBC)
Lead author: Hope S. Rugo, MD
Session: Oral Session: General Session 3 (9:30 am-11:30 am)
Location: Thursday, December 7, 10:45 am, Room: Hall 3
Learn more about the trial.

CALGB (Alliance) 40502
Physical Activity, Weight and Outcomes in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from CALGB 40502 (Alliance)
Lead author: JA Ligibel, MD
Session: Poster Session 1: Prognostic and Predictive Factors: other (5 pm-7 pm)
Location: Wednesday, December 6, 5 pm, Room: Hall 1
Learn more about the trial.

CALGB (Alliance) 40903
Primary Endocrine Therapy for ER-Positive Ductal Carcinoma In Situ (DCIS) CALGB 40903 (Alliance)
Lead author: E. Shelley Hwang, MD
Session: Oral Session: General Session 5 (9:30 am-11:30 am)
Location: Friday, December 8, 10:30 am, Room: Hall 3
Learn more about the trial.

CALGB (Alliance) 40502
Trajectory Patterns of Circulating Tumor Cells (CTC) in Chemotherapy-Treated Metastatic Breast Cancer (MBC) Patients Predict Poor Clinical Outcomes: CALGB 40502 (Alliance) / NCCTG N063H
Lead author: Mark Jesus M. Magbanua, MD
Session: Poster Session 2: Detection/Diagnosis: Circulating tumor cells (7 am-9 am)
Location: Thursday, December 7, 7 am, Room: Hall 1
Learn more about the trial.

CALGB (Alliance) 40601 
Independent Validation of the PAM50-based Chemo-Endocrine Score (CES) in Hormonal Receptor Positive (HR+)/HER2+ Breast Cancer (BC) Treated with Neoadjuvant Anti-HER2-Based Therapy
Lead author: Tomás Pascual, MD
Session: Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies (7 am-9 am)
Location: Thursday, December 7, 7 am, Room: Hall 1
Learn more about the trial.

CALGB (Alliance) 40601
Invasive Disease-free Survival and Gene Expression Signatures in CALGB (Alliance) 40601, A Randomized Phase III Neoadjuvant Trial of Dual HER2-Targeting with Lapatinib Added to Chemotherapy Plus Trastuzumab
Lead author: Ian E. Krop, MD
Session: Oral Session: General Session 3 (9:30 am-11:30 am)
Location: Thursday, December 7, 9:45 am, Room: Hall 3  
Learn more about the trial.
 
IBCSG-24-02 (SOFT-TEXT)
Concurrent and Sequential Initiation of Ovarian Function Suppression with Chemotherapy in Premenopausal Women with Endocrine-Responsive Early Breast Cancer: An Exploratory Analysis of TEXT and SOFT
Lead author: MM Regan, MD
Session: General Session 4 (3:15 pm- 5 pm)
Location: Thursday, December 7, 3:45 pm
Learn more about the trial.
   
IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT)
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane (E) Plus Ovarian Function Suppression (OFS) vs Tamoxifen (T) Plus OFS in Premenopausal Women with Hormone Receptor Positive (HR+) Early Breast Cancer (BC): Update of the Combined TEXT and SOFT Trials
Lead author: O. Pagani, MD
Session: Oral Session: General Session 4 (3:15 pm-5 pm)
Location: Thursday, December 7, 3:30 pm, Room: Hall 3
Learn more about the trials - IBCSG-24-02 (SOFT-TEXT) and IBCSG-25-02 (TEXT)

 

For other articles in the December issue of the Alliance E-News newsletter, see below.